Loading...

Royalty Pharma plc

RPRX•NASDAQ
Healthcare
Biotechnology
$49.38
$-0.26(-0.52%)
U.S. Market opens in 49h 27m

Royalty Pharma plc (RPRX) Stock Overview

Explore Royalty Pharma plc’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap21.2B
P/E Ratio27.78
EPS (TTM)$1.78
ROE0.12%
Fundamental Analysis

AI Price Forecasts

1 Month$47.41
3 Months$47.21
1 Year Target$50.45

RPRX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Royalty Pharma plc (RPRX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 61.04, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $50.45.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 27.78 and a market capitalization of 21.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-0.52%
5-Day Change
1.60%
1-Month Change
8.36%
3-Month Change
22.23%
6-Month Change
32.53%
Year-to-Date (YTD) Change
27.80%
1-Year Change
54.17%
3-Year Change
37.82%
5-Year Change
9.88%
All-Time (Max) Change
10.97%

Contact Information

https://www.royaltypharma.com
212 883 0200
110 East 59th Street, New York City, NY, 10022

Company Facts

75 Employees
IPO DateJun 16, 2020
CountryUS
Actively Trading

Frequently Asked Questions